Hmn-384 -

We evaluated the antiproliferative activity of HMN-384 across a panel of breast cancer cell lines. HMN-384 exhibited potent cytotoxicity in TNBC lines (MDA-MB-231, BT-549) with GI50 values ranging from 12 to 28 nM, whereas luminal breast cancer lines (MCF-7, T47D) were significantly less sensitive.

Unveiling HMN-384: The Future of Innovation and Technology HMN-384

One of the earliest and most intriguing connections to HMN-384 is found in the realm of scientific research. A search of online databases and academic journals reveals that HMN-384 has been referenced in several studies, often in the context of chemistry, biology, or pharmacology. For instance, some sources mention HMN-384 as a chemical compound, possibly a small molecule or a drug candidate, being investigated for its potential therapeutic applications. A search of online databases and academic journals

Biochemical kinase assays revealed that HMN-384 potently inhibits CDK11 kinase activity with an IC50 of . To assess selectivity, HMN-384 was screened against a panel of 468 kinases using the KinomeScan assay at a concentration of 1 µM. HMN-384 demonstrated exquisite selectivity, with a selectivity score (S(35)) of 0.01. Notably, HMN-384 showed >1,000-fold selectivity over CDK4 and CDK6, and >500-fold selectivity over CDK9. This distinct selectivity profile suggests that HMN-384 avoids the neutropenia and gastrointestinal toxicity associated with CDK4/6 and CDK9 inhibition, respectively. To assess selectivity, HMN-384 was screened against a